MPN

Can a drug used to treat arthritis also be a way to treat polycythemia vera (PV), and save patients with the blood cancer money?

MPN treatment and diagnostic strategies have come a long way in recent years, but still have a ways to go.

Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.

In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.

Patients with MPNs face unique challenges with depression and sexual intimacy. Sandra Allen-Bard, BSN, MSN, AOCNP, ANCC, discusses a recent study conducted to better understand these issues.

Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

Clinical trial enrollment is vital for the field of MPN treatment to continue to progress forward.

While clinical trials are paving the way for new treatments to treat hematologic malignancies, but many patients are apprehensive to participate in them after considering the costs.

An ongoing trial is seeking to find out if a patient with an MPN can improve their health status through nutritional interventions.

After publishing them in October 2016,the National Comprehensive Cancer Network (NCCN) is already seeking to update and expand their guidelines for diagnosing and treating patients with myeloproliferative neoplasms (MPNs).

Finola Hughes from TV's "General Hospital" and Ellen K. Ritchie, M.D. are teaming up to raise awareness for polycythemia vera.

Andrew Schorr, founder of Patient Power and Patient Empowerment and 2016 MPN Hero, discusses how his background in journalism led him to patient advocacy.

Ross L. Levine, M.D., physician-scientist, director of the Memorial Sloan Kettering (MSK) Center for Hematologic Malignancies and 2016 MPN Hero, discusses the work at his lab that he is currently excited about.

Michael J. Mauro, M.D., discusses advances in treating myeloproliferative disorders.

Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs.

Patricia K. Koenig, patient advocate and 2016 MPN Hero, discusses living with polycythemia vera (PV).

The clinical hold on pacritinib was recently lifted by the US Food and Drug Administration (FDA).

Erin H. Blackwell, R.N., B.S.N., O.C.N., oncology nurse and 2016 MPN Hero, discusses what to discuss with newly diagnosed patients with MPNs to ensure the best possible care.

Bonnie Joyce Blankert, caregiver and 2016 MPN Hero, discusses the importance of remaining calm when caregiving for a loved one with MPN who recently had a stem cell transplant.

After being diagnosed with polycythemia vera, David Wallace, who publishes PV Reporter and MPN Cancer Connection, quickly learned that he must be his own advocate.

Ann Brazeau, founder and CEO of MPN Advocacy & Education International and a 2016 MPN Hero, discusses the importance and benefits of MPN support groups.

A recent study examined the symptoms and impairments for patients with MPNs.

Oncologist, researcher and Pulitzer Prize-winning author Siddhartha Mukherjee, M.D., Ph.D, talked with CURE on the future of treating MPNs.

For the first time in history, MPN guidelines have been set by the NCCN.

Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).

Ropeginterferon alfa-2b is noninferior to hydroxyurea (HU) when it comes to complete hematologic response to treat PV.